Department of Pharmacy Practice, Nazareth College of Pharmacy, Othera, Thiruvalla, Kerala.
World Journal of Biology Pharmacy and Health Sciences, 2026, 27(01), 186–193
Article DOI: 10.30574/wjbphs.2026.27.1.0406
Received on 20 June 2026; revised on 25 July 2026; accepted on 28 July 2026
Lennox-Gastaut syndrome (LGS) represents a serious form of developmental and epileptic encephalopathy, which is defined by drug-resistant seizures of various types, cognitive problems and typical EEG slow spike wave discharges. LGS starts in childhood and is usually associated with a high neurologic, developmental, and psychosocial burden. The cause of LGS is different and can be represented by structural, genetic, metabolic problems, infections and idiopathic forms of LGS. Even with all progress in diagnostic and therapeutic approaches, a complete cure of seizures is difficult to attain for most of the LGS patients; thus, many individuals remain affected with seizures throughout their lifetime. The diagnosis is made based on clinical history, semiology of seizures, specific EEG pattern, neuroimaging and genetic testing. Treatment is complex and involves the use of anti-seizure medications, dietary management, neuroimaging, surgery, rehabilitation, and psychosocial support. New therapeutic approaches approved in recent years and precision medicine have changed the treatment and improved prognosis in some LGS cases.
Lennox-Gastaut Syndrome; Developmental and epileptic encephalopathy; Drug-resistant epilepsy; Electroencephalopathy; Anti-seizure medications
Get Your e Certificate of Publication using below link
Preview Article PDF
Achsah Achu Benoy, Anjali S and Philip Jacob. Lennox–Gastaut Syndrome: A Narrative Review of Etiology, Pathophysiology, Clinical Features, Diagnosis, and Management. World Journal of Biology Pharmacy and Health Sciences, 2026, 27(01), 186–193. Article DOI: https://doi.org/10.30574/wjbphs.2026.27.1.0406